About: Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.15 (-6.11%)
FATE NASDAQ Fate Therapeutics Inc
Fate Therapeutics Inc share price
FATE price activity
Último preço
$ 2,150
Variação (24h)
-0,14 USD (-6,11%)
Volume
860.85K
Volume (média 4 sem.)
-
Abertura
$ 2,28
Variação do dia
$ 2,14 - $ 2,30
Fechamento anterior
$ 2,29
Último negócio
07 Oct, 8:00 pm GMT+0
Atrasado
07 Oct, 8:00 pm GMT+0
FATE price performance
Atrasado
07 Oct, 8:00 pm GMT+0
quote.marketSignals